Compare PRAX & GL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRAX | GL |
|---|---|---|
| Founded | 2015 | 1900 |
| Country | United States | United States |
| Employees | N/A | 3695 |
| Industry | Biotechnology: Pharmaceutical Preparations | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 10.7B |
| IPO Year | 2020 | N/A |
| Metric | PRAX | GL |
|---|---|---|
| Price | $331.13 | $145.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 11 |
| Target Price | ★ $572.13 | $166.82 |
| AVG Volume (30 Days) | 345.8K | ★ 412.3K |
| Earning Date | 05-01-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 0.74% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.74 |
| Revenue Next Year | $6,395.88 | $5.59 |
| P/E Ratio | ★ N/A | $10.21 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.79 | $111.13 |
| 52 Week High | $354.87 | $152.71 |
| Indicator | PRAX | GL |
|---|---|---|
| Relative Strength Index (RSI) | 57.17 | 60.20 |
| Support Level | $282.49 | $135.08 |
| Resistance Level | $327.65 | $147.44 |
| Average True Range (ATR) | 17.60 | 2.82 |
| MACD | 2.86 | 1.00 |
| Stochastic Oscillator | 81.68 | 74.12 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into three reportable segments: life insurance, supplemental health insurance and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.